Literature DB >> 30103277

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

D Jakimovski1, S Gandhi1, I Paunkoski1, N Bergsland1, J Hagemeier1, D P Ramasamy1, D Hojnacki2, C Kolb2, R H B Benedict2, B Weinstock-Guttman2, R Zivadinov1,3.   

Abstract

BACKGROUND: Cardiovascular diseases (CVDs) are more frequent in multiple sclerosis (MS) patients when compared to controls. In particular, CVDs are linked with higher accumulation of lesions and advanced brain atrophy.
OBJECTIVE: To investigate whether CVDs contribute to accelerated lesion accumulation and brain atrophy over 5 years in patients with MS.
METHODS: 194 MS patients and 43 controls without neurologic disease were followed for 5 years. Full physical, neurological evaluation, and structured questionnaire investigating CVD and risk factors (hypertension, hyperlipidemia, heart disease, smoking, diabetes, obesity/overweight) were collected using interview-based questionnaire and further cross-reference with electronic medical records. Lesion and brain atrophy outcomes were assessed with 3T MRI. ANCOVA adjusted for age, gender, and disease duration were used accordingly. False discovery rate correction was performed using Benjamini-Hochberg correction.
RESULTS: Patients with diagnosis of heart disease showed higher white matter and whole brain volume loss compared to those without (-4.2% vs. -0.7%, P = 0.01 and -3.4% vs. -1.6%, P = 0.01, respectively). The percentage lateral ventricle volume change in MS patients with hypertension was higher compared to non-hypertensive patients (24.5% vs. 14.1%, P = 0.05). Hyperlipidemia, smoking, and obesity/overweight were not associated with progression of MRI-derived outcomes. CVDs did not contribute to larger lesion volume accrual over the 5-year period. The presence of CVDs was not associated with MRI-derived changes in the controls.
CONCLUSIONS: Hypertension and heart disease contribute to advanced brain atrophy in MS patients. CVDs did not contribute to additional lesion accrual. CVD comorbidities in MS patients may contribute to neurodegenerative tissue injury that can be detected with brain MRI.
© 2018 EAN.

Entities:  

Keywords:  zzm321990MRIzzm321990; brain atrophy; heart disease; hypertension; lateral ventricular volume; multiple sclerosis

Mesh:

Year:  2018        PMID: 30103277     DOI: 10.1111/ene.13769

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  18 in total

1.  Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.

Authors:  Dejan Jakimovski; Ralph Hb Benedict; Karen Marr; Sirin Gandhi; Niels Bergsland; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Mult Scler       Date:  2019-01-09       Impact factor: 6.312

2.  Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Authors:  Elina Misicka; Corriene Sept; Farren B S Briggs
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

3.  Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.

Authors:  Olwen C Murphy; Ohemaa Kwakyi; Mustafa Iftikhar; Sidra Zafar; Jeffrey Lambe; Nicole Pellegrini; Elias S Sotirchos; Natalia Gonzalez-Caldito; Esther Ogbuokiri; Angeliki Filippatou; Hunter Risher; Norah Cowley; Sydney Feldman; Nicholas Fioravante; Elliot M Frohman; Teresa C Frohman; Laura J Balcer; Jerry L Prince; Roomasa Channa; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2019-05-16       Impact factor: 6.312

4.  Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.

Authors:  Dejan Jakimovski; Niels Bergsland; Michael G Dwyer; Kunsang Choedun; Karen Marr; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Eur Radiol       Date:  2022-04-01       Impact factor: 7.034

5.  Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.

Authors:  Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2020-04-16       Impact factor: 6.312

6.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

7.  Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

Authors:  E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; D P Ramasamy; D Hojnacki; A A Lizarraga; C Kolb; S Eckert; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

Review 8.  Epidemiology and treatment of multiple sclerosis in elderly populations.

Authors:  Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

9.  Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study.

Authors:  Eleonora Tavazzi; Dejan Jakimovski; Jens Kuhle; Jesper Hagemeier; Osman Ozel; Murali Ramanathan; Christian Barro; Niels Bergsland; Davorka Tomic; Harald Kropshofer; David Leppert; Zuzanna Michalak; Norah Lincoff; Michael G Dwyer; Ralph H B Benedict; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-18

Review 10.  Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis.

Authors:  Joanna Saluk-Bijak; Angela Dziedzic; Michal Bijak
Journal:  Cells       Date:  2019-02-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.